Stocks · News reference
Climb Bio shares are trading higher after Beijing Mabworks Biotech announced the dosing of the first patient in a Phase 2 trial for immunoglobulin A nephropathy in China, conducted in collaboration with Climb Bio.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 14, 2026, 6:15 PM
- Checked
- Aug 14, 2026, 6:15 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Wedbush Reiterates Outperform on Climb Bio, Maintains $20 Price Target
Wedbush analyst Laura Chico reiterates Climb Bio (NASDAQ:CLYM) with a Outperform and maintains $20 price target.
Read original at benzinga8-K filing — Climb Bio, Inc. (CLYM)
Filed: 2026-08-14 AccNo: 0001193125-26-350596 Size: 141 KB Item 8.01: Other Events
Read original at edgar